Company profile
MACROGENICS INC
NASDAQ:MGNXBiotechnology: Pharmaceutical Preparations
Drug pipeline (4)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| RETIFANLIMAB | phase2_3 | — | 4 | completed, terminated, withdrawn |
| ENOBLITUZUMAB | phase1 | — | 2 | completed, terminated |
| OBRINDATAMAB | phase1 | — | 1 | terminated |
| PRV-3279 | phase1 | — | 2 | completed, terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (38)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05848011 | phase2 | completed | 2023-09-28 | 2026-02-19 | MacroGenics | A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer |
| NCT06730347 | phase2 | recruiting | 2025-05-01 | 2027-07-01 | MacroGenics | A Study of Lorigerlimab in Participants With Advanced Solid Tumors |
| NCT05293496 | phase1 | completed | 2022-04-19 | 2025-06-24 | MacroGenics | A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors |
| NCT06242470 | phase1 | recruiting | 2024-03-06 | 2028-05-01 | MacroGenics | A Study of MGC026 in Participants With Advanced Solid Tumors |
| NCT06723236 | phase1 | recruiting | 2025-02-13 | 2026-11-01 | MacroGenics | A Study of MGC028 in Participants With Advanced Solid Tumors |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 761150 | BLA | MacroGenics Inc. | ||||
Loading… | ||||||